Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01305538 · ClinicalTrials.gov registry record · Phase 2
Crossover Post-herpetic Neuralgia (PHN)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT01305538 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 100 participants.
The verdict
NCT01305538, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy of study drug (BMS-954561) as compared to placebo in the treatment of patients with post-herpetic neuralgia (PHN).
Interventions
- DRUG Placebo
- DRUG BMS-954561
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01305538
The ClinicalTrials.gov registry entry for NCT01305538 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01305538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01305538 about?
NCT01305538 is a clinical study titled "Crossover Post-herpetic Neuralgia (PHN)". The purpose of the study is to evaluate the efficacy of study drug (BMS-954561) as compared to placebo in the treatment of patients with post-herpetic neuralgia (PHN).
What is the current status of trial NCT01305538?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2011-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01305538?
The interventions under investigation include: Placebo (DRUG), BMS-954561 (DRUG).
Who is sponsoring clinical trial NCT01305538?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.